Danaher Corporation Stock News

Danaher stock (NYSE: DHR), a conglomerate with products in life sciences, biotechnology, and diagnostics fields, recently posted its Q1 results that exceeded the street expectations. The company repor

While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.

PulteGroup received an added data boost, Danaher's markets are looking up, and JetBlue collapses, despite a not-as-bad-as-feared loss.

Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street e

The medical company reported first-quarter adjusted earnings of $1.92 a share, beating Wall Street's call for $1.72.

Danaher (DHR) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.72 per share. This compares to earnings of $2.36 per share a year ago.

Danaher beat quarterly profit and sales expectations on Tuesday, driven by strength in its diagnostics and bioprocessing businesses, sending shares of the life sciences firm up more than 7% before the

Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.

Evaluate the expected performance of Danaher (DHR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for

Short-term bonds currently yield more than stocks, indicating a shift in the investment environment. Investors should focus on companies with healthy balance sheets, pricing power, and that are tradin

Danaher (DHR) is set to benefit from strength across its businesses, acquired assets and shareholder-friendly policies.

Healthcare's impact on the economy cannot be overstated. According to the American Medical Association, the U.S. spends more than $4 trillion a year on healthcare, which works out to nearly $13,000 pe

In the closing of the recent trading day, Danaher (DHR) stood at $244.28, denoting a +0.98% change from the preceding trading day.